Tracon Jumps 10% on Final Data of Phase 1b Trial of TRC105 in Renal Cell Carcinoma

Tracon Pharmaceuticals (TCON) shares were 10% higher Monday morning after the clinical-stage biopharmaceutical company said that the final updated results from its phase 1b trial combining TRC105 with Inlyta in patients with advanced or metastatic renal cell carcinoma achieved a median progression free survival of 11.3 months.

The study also demonstrated that the recommended phase 2 dose of TRC105 of 10 mg/kg dosed weekly was well-tolerated in combination with Inlyta and no dose limiting toxicities were observed, and that the most common adverse events were low grade epistaxis, headache, fatigue, diarrhea, and gingival bleeding.

All patients in the phase 1b trial have now completed treatment, and the randomized phase 2b trial is now currently enrolling patients with advanced or metastatic renal cell carcinoma. Topline data from the phase 2b study is expected to be available in H1 2017.

Leave a Comment